

Group Art Unit: 1201

Examiner: Richter

IITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent 5,270,317

Claude BERNHART et al.

Serial No. 07/794,497

Filed: November 20, 1991

For: N-Substituted heterocyclic derivatives,

> their preparation and the pharmaceutical: compositions in which they are present

TERMINAL DISCLAIMERTEN! & TRADEMARK OFFICE

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

SEP 9 1994

CERTIFICATE OF CORRECTION BR. Your Petitioner, ELF SANOFI (henceforth referred to as "Assignee"), having a place of business at 32-34 rue Marbeuf, Paris, France, represents that it is the owner by assignment of the entire right and title to the above-captioned patent and the invention and improvements therein disclosed for the United States by virtue of an Assignment from the inventors, Claud Bernhart et al., to SANOFI, dated February 3, 1992, and recorded at Reel 6011, Frame 0616, on February 11, 1992. SANOFI changed its name to ELF SANOFI on January 31, 1992, as reflected in the change of name document which was recorded in connection with the above patent on June 22, 1993, at Reel 6583, Frame 0399.

Assignee, who is also owner of the entire right and title to U.S. Patent Number 5,268,375 by an Assignment recorded on April 15, 1992, at Reel 6092, Frame 0530, hereby disclaims the terminal part of the above-captioned patent which would extend beyond the expiration date of the full statutory term of U.S. Patent Number 5,268,375, and hereby agrees that the above-captioned patent shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent Number 5,268,375, this agreement to run with the above-captioned patent to be binding upon the grantee, its successors or assigns. Notwithstanding the above disclaimer, Assignee does not waive any rights available under the provisions of 35 U.S.C. §§155 and 156.

U.S. Patent No. 5,270,317

Assignee does not disclaim any terminal part of the above captioned patent prior to the expiration date of the full statutory term of U.S. Patent 5,268,375 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term, except for the separation of legal title stated above. Assignee does not disclaim any terminal part of the above captioned patent resulting from any extension of that patent granted under the provisions of 35 U.S.C. §§155, 155(a) and 156.

Assignee certifies under 37 C.F.R. §3.73(b) that the evidentiary documents have been reviewed and, to the best of assignee's knowledge, title is in the assignee as reflected in the assignments and change of name documents referenced above.

Signed at Paris, France

this day of May 1994.

Respectfully submitted,

ELF SANOFI

By: V

Title:

Ronald SCHAPIRA

Chef de la Division Propriété industrialie

Director of Patents and Trademarks